MENLO PARK, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the results from GRACE, the Phase 3 trial of its proprietary selective cortisol modulator relacorilant in patients with hypercortisolism (Cushing’s syndrome), will be presented at the Endocrine Society (ENDO) annual meeting in Boston (June 3) and the Heart in Diabetes (HiD) conference in Philadelphia (June 7)..

加利福尼亚州门洛帕克，2024年6月3日（环球通讯社）--Corcept Therapeutics Incorporated（NASDAQ:CORT）是一家商业阶段公司，致力于通过调节激素皮质醇的作用来发现和开发治疗严重内分泌，肿瘤，代谢和神经系统疾病的药物，今天宣布GRACE（其专有选择性皮质醇调节剂相关剂治疗皮质醇增多症（库欣综合征）患者的3期试验）的结果将在波士顿内分泌学会（ENDO）年会（6月3日）和费城心脏病（HiD）会议（6月7日）上发表。。

ENDO 2024, Boston Convention & Exhibition Center

ENDO 2024，波士顿会展中心

Late-Breaking Poster Presentation: Open-label Results From GRACE, A Phase 3 Double-blind, Randomized-withdrawal Study Of The Selective Glucocorticoid Receptor Modulator Relacorilant For The Treatment Of Endogenous Hypercortisolism (Cushing Syndrome)

晚期突破性海报展示：GRACE的开放标签结果，GRACE是一项选择性糖皮质激素受体调节剂相关剂治疗内源性皮质醇增多症（库欣综合征）的3期双盲随机戒断研究

Date & Time: Monday, June 3, 2024, 12:00-1:30 pm ET

Date & Time: Monday, June 3, 2024, 12:00-1:30 pm ET

Presenter: Rosario Pivonello, MD, PhD, Principal Investigator of the GRACE study and Professor of Endocrinology at Università Federico II di Napoli, Italy

主持人：罗萨里奥·皮沃内洛（Rosario Pivonello），医学博士，博士，GRACE研究首席研究员，意大利那不勒斯费德里科第二大学内分泌学教授

Session: P108 - Late-Breaking Poster Presentations: Day 3

课程：P108-最新海报展示：第3天

8th Heart in Diabetes Conference, Hilton Penn’s Landing

第八届糖尿病心脏会议，希尔顿·佩恩登陆

Oral Presentation: Hypercortisolism Impact on Hypertension and Hyperglycemia and Beyond

口头介绍：皮质醇增多症对高血压和高血糖等的影响

Date & Time: Friday, June 7, 2024, 3:50-4:00 pm ET

日期、时间：美国东部时间2024年6月7日星期五下午3:50-4:00

Presenter: Ralph DeFronzo, MD, chief of the Diabetes Division and professor of medicine at UT Health San Antonio

主持人：拉尔夫·德夫隆佐（RalphDefronzo），医学博士，糖尿病科科长，圣安东尼奥UT Health大学医学教授

Session: Hypercortisolism Implication to Cardiorenal & Metabolic Diseases

会议：皮质醇增多症对心肾和代谢疾病的影响

Oral Presentation: Medical Treatment of Hypercortisolism with Relacorilant: Final Results of the Phase 3 GRACE Study

口头介绍：用相关药物治疗皮质醇增多症：第3阶段GRACE研究的最终结果

Date & Time: Friday, June 7, 2024, 4:00-4:20 pm ET

日期、时间：美国东部时间2024年6月7日星期五下午4:00-4:20

Presenter: Rosario Pivonello, MD, PhD, Principal Investigator of the GRACE study and Professor of Endocrinology at Università Federico II di Napoli, Italy

主持人：罗萨里奥·皮沃内洛（Rosario Pivonello），医学博士，博士，GRACE研究首席研究员，意大利那不勒斯费德里科第二大学内分泌学教授

Session: Hypercortisolism Implication to Cardiorenal & Metabolic Diseases

会议：皮质醇增多症对心肾和代谢疾病的影响

Each of the above presentations will be available on Corcept.com following the event.

活动结束后，上述每个演示文稿都将在Corcept.com上发布。

About Relacorilant

关于Relarelant

Relacorilant is a selective cortisol modulator that binds to the glucocorticoid receptor but does not bind to the body's other hormone receptors. Corcept is studying relacorilant in a variety of serious disorders in addition to Cushing’s syndrome, including ovarian, adrenal and prostate cancer. Relacorilant is proprietary to Corcept and is protected by composition of matter, method of use and other patents.

Relacorilant是一种选择性皮质醇调节剂，与糖皮质激素受体结合，但不与身体其他激素受体结合。Corcept正在研究库欣综合征以外的多种严重疾病的相关性，包括卵巢癌、肾上腺癌和前列腺癌。Relacorilant是Corcept的专有技术，受物质成分、使用方法和其他专利的保护。

Relacorilant has orphan drug designation in the United States and the European Union for the treatment of Cushing’s syndrome..

Relacorilant在美国和欧盟被指定为治疗库欣综合征的孤儿药。。

About Corcept Therapeutics

关于Corcept Therapeutics

For over 25 years, Corcept’s focus on cortisol modulation and its potential to treat patients with a wide variety of serious disorders has led to the discovery of more than 1,000 proprietary selective cortisol modulators. Corcept is conducting advanced clinical trials in patients with hypercortisolism, solid tumors, amyotrophic lateral sclerosis (ALS) and liver disease.

25年来，Corcept专注于皮质醇调节及其治疗各种严重疾病患者的潜力，导致发现了1000多种专有选择性皮质醇调节剂。Corcept正在对皮质醇增多症、实体瘤、肌萎缩侧索硬化症（ALS）和肝病患者进行高级临床试验。

In February 2012, the company introduced Korlym®, the first medication approved by the U.S. Food and Drug Administration for the treatment of patients with Cushing’s syndrome. Corcept is headquartered in Menlo Park, California. For more information, visit Corcept.com..

2012年2月，该公司推出了Korlym®，这是美国食品和药物管理局批准用于治疗库欣综合征患者的第一种药物。Corcept总部位于加利福尼亚州门洛帕克。有关更多信息，请访问Corcept.com。。

Forward-Looking Statements

前瞻性声明

Statements in this press release, other than statements of historical fact, are forward-looking statements based on our current plans and expectations that are subject to risks and uncertainties that might cause our actual results to differ materially from those expressed or implied by such statements.

本新闻稿中的声明（历史事实声明除外）是基于我们当前计划和预期的前瞻性声明，这些声明具有风险和不确定性，可能导致我们的实际结果与此类声明中明示或暗示的结果存在重大差异。

These risks and uncertainties include, but are not limited to, our ability to operate our business; risks related to the study and development of Korlym, relacorilant, dazucorilant, miricorilant and our other product candidates, including their clinical attributes, regulatory approvals, mandates, oversight and other requirements; and the scope and protective power of our intellectual property.

这些风险和不确定性包括但不限于我们经营业务的能力；与Korlym，relacorilant，dazucorilant，miricorilant和我们的其他候选产品的研究和开发相关的风险，包括其临床属性，监管批准，授权，监督和其他要求；以及我们知识产权的范围和保护能力。

These and other risks are set forth in our SEC filings, which are available at our website and the SEC’s website..

这些和其他风险在我们的SEC文件中有规定，这些文件可在我们的网站和SEC的网站上找到。。

In this press release, forward-looking statements include those concerning: relacorilant, including its clinical attributes and potential to become a treatment for patients with Cushing’s syndrome or any other disorder, regulatory oversight of relacorilant, its commercial prospects and the scope and protective power of our intellectual property.

在本新闻稿中，前瞻性声明包括：relacorilant，包括其临床属性和成为库欣综合征或任何其他疾病患者治疗的潜力，relacorilant的监管监督，其商业前景以及我们知识产权的范围和保护力。

We disclaim any intention or duty to update forward-looking statements made in this press release..

我们不打算或有义务更新本新闻稿中的前瞻性声明。。

CONTACT

联系人

Investor inquiries:

投资者咨询：

ir@corcept.com

ir@corcept.com

Media inquiries:

媒体查询：

communications@corcept.com

communications@corcept.com

www.corcept.com

www.corcept.com